Videos

Mr. Ehas shares his initial treatment experience and response to chemo, while Anand Shah, PharmD, BCOP describes an oncology pharmacists’ role in patient education and adverse event management.

Dr Jain discusses frontline treatment options, cisplatin eligibility criteria, and therapy considerations for metastatic bladder cancer.

Nearing the end of their program, panelists consider a patient with anemic myelofibrosis and optimal treatment strategies in that setting.

In light of the current treatment armamentarium for myelofibrosis, key opinion leaders in the field discuss optimal sequencing of available JAK inhibitors.

In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.

Expert Wilson Gonsalves, MD, shares clinical data in multiple myeloma centered on the distinction between biochemical versus clinical progression.

Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.

Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.

Experts discuss the challenges of grading chronic graft-versus-host disease using NIH criteria, noting the importance of a common language, and considering patient symptoms, performance status, and organ involvement in assessing severity.

Nelson Chao, MD, MBA, presents the clinical scenario of a 53-year-old man with chronic graft-versus-host disease and highlights the complexities of distinguishing between symptoms of acute and chronic GVHD.

Expert panelists consider how updated data from the CLEAR trial of lenvatinib + pembrolizumab in advanced clear cell RCC have impacted their real-world clinical practice.

Leaders in bladder cancer management consider factors that aid in their selection of second-line therapy.

Centering discussion on the KCRS 2023 annual meeting, experts in renal cell carcinoma elucidate data from the CLEAR and TRAVERSE studies in clear cell disease.

In light of individual patient needs, perspectives are shared on the roles of palliative radiation and treatment breaks in the setting of advanced bladder cancer.

Shared patient perspectives and conversation centered around collaboration in clinical care for metastatic bladder cancer, including the oncology pharmacists’ role in treatment decisions.

Rohit Jain, MD, MPH provides an overview of metastatic bladder cancer, discussing differences in urothelial carcinoma based on location, patient presentations, diagnosis, and staging.

Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.

Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.

Continuing their focus on optimizing JAK inhibitor therapy in myelofibrosis, panelists highlight dosing and adverse event management strategies.

A brief discussion on the role that JAK inhibitors play in cytopenic myelofibrosis and how best to optimize care with sequencing and dose adjustment.

In the last presentation of the session, Abhishek Mangaonkar, MBBS, details clinical trial data with low-dose dasatinib in patients with chronic myeloid leukemia.

Covering the first of two abstracts, Wilson Gonsalves, MD, reviews data from the IKEMA study of isatuximab KD in patients with relapsed/refractory multiple myeloma.

The expert panel offers closing thoughts on MRD assessment and how ctDNA has been incorporated into clinical practice in the treatment of colorectal cancer.

In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.

Panelists from both the Mayo Clinic and UT Southwestern comment on data from ALLIANCE A061202 and consider the role of isatuximab in patients with relapsed/refractory multiple myeloma.

Closing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.

Key safety data from the indirect comparison study of acalabrutinib versus zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Experts discuss recent data on a triplet combination therapy for patients with advanced non-clear cell renal cell carcinoma.

Drs Robert Motzer and Moshe Ornstein discuss the results of the KEYNOTE-B61 study in patients with non-clear cell renal cell carcinoma.

Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.